AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02954913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous Resection
Description: Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
Study NCT00194012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Addressed in arm description.
Study NCT00194012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Addressed in arm description.
Study NCT03455855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream System
Description: including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
Study NCT00461903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
Study NCT00461903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perindopril
Description: Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
Study NCT02670590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet
Study NCT05158946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Oriented Group Training
Description: This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
Study NCT02864797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health related quality of life collected via CHES
Description: Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
Study NCT05083767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.
Study NCT05083767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group was advised to their normal physical activity level, diet, and medication.
Study NCT02805842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus BID
Description: Administration of Tacrolimus BID
Study NCT02805842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf QD
Description: administration of Advagraf QD
Study NCT03932474 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SAMEUp
Description: One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
Study NCT03932474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
Study NCT01991184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Multiple escalating doses
Study NCT06650241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Study NCT06650241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lip Bumper Therapy
Study NCT06650241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Twin-Block Therapy
Study NCT00774722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 10% ointment, three times daily for 14 days
Study NCT00774722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: 10% ointment, three times daily for 14 days
Study NCT03143829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eSSET-CINV
Description: This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
Study NCT02985515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell training
Description: Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
Study NCT01320176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational HIV vaccine dose A
Description: The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
Study NCT03143829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eSSET-CINV
Description: This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
Study NCT04293887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon α1β
Description: Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
Study NCT01400594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTU-520 Patch
Description: Terbinafine hydrochloride patch
Study NCT01320176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational HIV vaccine dose B
Description: The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
Study NCT03503201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chromium
Description: chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
Study NCT01400594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Treatment with Placebo Patch
Study NCT04518735 — intervention group
Intervention type: OTHER
Intervention: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
Description: Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
Study NCT00982319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract
Description: 100 µmols of sulforaphane (dissolvable)
Study NCT00982319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mango juice
Description: 150 mL of mango juice
Study NCT00982319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mango juice
Description: 150 mL of mango juice
Study NCT03229551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
Study NCT03229551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
Study NCT03859232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delta Dry® Waterproof Pantaloon
Description: Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
Study NCT03859232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cotton Padding
Description: Cast with traditional cotton liner.
Study NCT02548013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: outpatient management
Description: patients if stable will be discharged to continue treatment at home
Study NCT02548013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient management
Description: patients will continue there treatment in hospital till delivery
Study NCT01766141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
Study NCT04833569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICG-PDT
Description: An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
Study NCT04833569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peri-implant mechanical debridement
Description: The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
Study NCT04833569 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: peri-implant mechanical debridement
Description: The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
Study NCT03621943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
Study NCT02206256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid capsules
Description: 2 times a day 1 capsule for 4 weeks before gastric bypass surgery
Study NCT02206256 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
Study NCT03621943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Cord Clamping
Description: The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
Study NCT01175382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral training
Description: Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
Study NCT01175382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine + tamsulosin
Description: Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
Study NCT01175382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Behavioral + Drug Therapy
Description: Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
Study NCT03791255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium silicate liner
Description: new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
Study NCT03791255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide liner
Description: Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
Study NCT02756169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
Study NCT03779282 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: see descriptions
Study NCT01371006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose
Description: efavirenz single dosing once daily
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Enbrel subcutaneously at Week 12
Description: sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Enbrel subcutaneously at Week 24
Description: sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Enbrel subcutaneously at Week 36
Description: sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Enbrel subdermally at Week 12
Description: sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Enbrel subdermally at Week 24
Description: sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Enbrel subdermally at Week 36
Description: sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PASI 75 n(%) subcutaneously at Week 12
Description: PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PASI 75 n(%) subcutaneously at Week 24
Description: PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PASI 75 n(%) subcutaneously at Week 36
Description: PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PASI 75 n(%) subdermally at Week 12
Description: PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PASI 75 n(%) subdermally at Week 24
Description: PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.